Related Experiment Video
Updated: Jul 4, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
The role of SPINK1 in ETS rearrangement-negative prostate cancers
Scott A Tomlins1, Daniel R Rhodes, Jianjun Yu
1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Abstract:
ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers ( approximately 10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers.
Insights
Researchers identified SPINK1 outlier expression in ETS rearrangement-negative prostate cancers. This finding is a potential noninvasive biomarker for predicting recurrence after surgery.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- ETS gene fusions are common in prostate cancer, but molecular drivers in ETS-negative cases remain largely unknown.
- Understanding these drivers is crucial for developing targeted therapies and improving patient outcomes.
Purpose of the Study:
- To identify molecular alterations in ETS rearrangement-negative prostate cancers.
- To investigate the role of SPINK1 expression as a potential biomarker and therapeutic target.
Main Methods:
- Utilized outlier meta-analysis (meta-COPA) to detect SPINK1 outlier expression.
- Validated mutual exclusivity between SPINK1 expression and ETS fusion status.
- Assessed SPINK1 detectability in urine and its predictive value for biochemical recurrence.
- Used the 22RV1 cell line to model SPINK1 outlier expression and test functional significance.
Main Results:
- Identified SPINK1 outlier expression in approximately 10% of ETS rearrangement-negative prostate cancers.
- Confirmed SPINK1 expression is mutually exclusive with ETS fusions.
- Demonstrated noninvasive detection of SPINK1 outlier expression in urine.
- Established SPINK1 outlier expression as an independent predictor of biochemical recurrence post-resection.
- Showcased SPINK1 knockdown in 22RV1 cells attenuating invasion, suggesting a functional role.
Conclusions:
- SPINK1 outlier expression represents a distinct molecular subtype of ETS rearrangement-negative prostate cancer.
- SPINK1 serves as a potential noninvasive biomarker for predicting prostate cancer recurrence.
- Targeting SPINK1 may offer a therapeutic strategy for a subset of aggressive prostate cancers.
Related Concept Videos
Abnormal Proliferation
RNA Splicing
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
